suramin has been researched along with HIV in 18 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin is a toxic agent that shows no virologic, immunologic, or clinical benefit in patients with HIV-related disease." | 6.66 | Lack of response to suramin in patients with AIDS and AIDS-related complex. ( Abrams, DI; Feorino, P; Gottlieb, MS; Kaplan, LD; Kaufman, L; Kiprov, D; Levy, JA; Volberding, PA; Wolfe, PR; Wong, R, 1987) |
| "Ten homosexual men with the acquired immunodeficiency syndrome were included in a serologic follow-up study (duration, 40 weeks) of human immunodeficiency virus (HIV) antigenemia." | 5.27 | Persistence of human immunodeficiency virus antigenemia in patients with the acquired immunodeficiency syndrome treated with a reverse transcriptase inhibitor, suramin. Ten-patient case-control study. ( Danner, SA; Eeftinck Schattenkerk, JK; Goudsmit, J; Lange, JM; Miedema, F; Paul, DA; Schellekens, PT; van Boxtel, CJ, 1988) |
| "The inhibitory activities of human immunodeficiency virus reverse transcriptase (HIV-RT) inhibitors PFA and Suramin against HIV-RT and equine infectious anemic virus reverse transcriptase (EIAV-RT) were studied in this paper." | 3.69 | Screening anti-HIV Chinese materia medica with HIV and equine infectious anemic virus reverse transcriptase. ( Chen, H; Quan, K; Sun, M; Tang, X; Zhang, X, 1994) |
| "Suramin sodium is a reverse transcriptase inhibitor with in vitro activity against the human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syndrome (AIDS)." | 3.67 | Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group. ( Cheson, BD; Gill, P; Groopman, JE; Kaplan, LD; Levine, AM; Mildvan, D; Poiesz, BJ; Rios, A; Volberding, PA; Wolfe, P, 1987) |
| "Suramin is a toxic agent that shows no virologic, immunologic, or clinical benefit in patients with HIV-related disease." | 2.66 | Lack of response to suramin in patients with AIDS and AIDS-related complex. ( Abrams, DI; Feorino, P; Gottlieb, MS; Kaplan, LD; Kaufman, L; Kiprov, D; Levy, JA; Volberding, PA; Wolfe, PR; Wong, R, 1987) |
| "Human African trypanosomiasis (HAT), otherwise known as sleeping sickness, has remained a disease with no effective treatment." | 2.42 | Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. ( Nok, AJ, 2003) |
| "Suramin is a potent inhibitor of the reverse transcriptase (RNA-directed DNA polymerase) of retroviruses, including the HTLV-III/LAV (human T-cell lymphotropic virus type III/lymphadenopathy-associated virus) reverse transcriptase." | 2.37 | Suramin in the treatment of AIDS: mechanism of action. ( De Clercq, E, 1987) |
| "Ten homosexual men with the acquired immunodeficiency syndrome were included in a serologic follow-up study (duration, 40 weeks) of human immunodeficiency virus (HIV) antigenemia." | 1.27 | Persistence of human immunodeficiency virus antigenemia in patients with the acquired immunodeficiency syndrome treated with a reverse transcriptase inhibitor, suramin. Ten-patient case-control study. ( Danner, SA; Eeftinck Schattenkerk, JK; Goudsmit, J; Lange, JM; Miedema, F; Paul, DA; Schellekens, PT; van Boxtel, CJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (61.11) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| De Clercq, E | 4 |
| Nok, AJ | 1 |
| Tang, X | 1 |
| Chen, H | 1 |
| Zhang, X | 1 |
| Quan, K | 1 |
| Sun, M | 1 |
| Neyts, J | 1 |
| Gabriel, JL | 1 |
| Mitchell, WM | 1 |
| Bhat, S | 1 |
| Otsuka, T | 1 |
| Srinivasan, A | 1 |
| Mahoney, CW | 1 |
| Azzi, A | 1 |
| Huang, KP | 1 |
| Vogt, M | 1 |
| Schooley, RT | 1 |
| Hirsch, MS | 1 |
| Nakashima, H | 1 |
| Harada, S | 1 |
| Yamamoto, N | 1 |
| Eeftinck Schattenkerk, JK | 1 |
| Danner, SA | 1 |
| Lange, JM | 1 |
| Paul, DA | 1 |
| van Boxtel, CJ | 1 |
| Miedema, F | 1 |
| Schellekens, PT | 1 |
| Goudsmit, J | 1 |
| Mitsuya, H | 1 |
| Looney, DJ | 1 |
| Kuno, S | 1 |
| Ueno, R | 1 |
| Wong-Staal, F | 1 |
| Broder, S | 2 |
| Yarchoan, R | 1 |
| Weber, J | 1 |
| Kaplan, LD | 2 |
| Wolfe, PR | 1 |
| Volberding, PA | 2 |
| Feorino, P | 1 |
| Levy, JA | 1 |
| Abrams, DI | 1 |
| Kiprov, D | 1 |
| Wong, R | 1 |
| Kaufman, L | 1 |
| Gottlieb, MS | 1 |
| Resnick, L | 1 |
| Markham, PD | 1 |
| Veren, K | 1 |
| Salahuddin, SZ | 1 |
| Gallo, RC | 1 |
| Cheson, BD | 1 |
| Levine, AM | 1 |
| Mildvan, D | 1 |
| Wolfe, P | 1 |
| Rios, A | 1 |
| Groopman, JE | 1 |
| Gill, P | 1 |
| Poiesz, BJ | 1 |
4 reviews available for suramin and HIV
| Article | Year |
|---|---|
Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.
Topics: Animals; Drug Resistance; HIV; Humans; Melarsoprol; Pentamidine; Suramin; Trypanocidal Agents; Trypa | 2003 |
Suramin in the treatment of AIDS: mechanism of action.
Topics: Acquired Immunodeficiency Syndrome; Cytopathogenic Effect, Viral; HIV; Humans; Reverse Transcriptase | 1987 |
Progress in the development of antiviral therapy for HTLV-III-associated diseases.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; HIV; Humans; Phosphonoace | 1987 |
Perspectives for the chemotherapy of AIDS.
Topics: Acquired Immunodeficiency Syndrome; Glycyrrhetinic Acid; Glycyrrhizic Acid; HIV; Humans; Polysacchar | 1988 |
2 trials available for suramin and HIV
| Article | Year |
|---|---|
[Chemotherapy and immunoprophylaxis of HIV infection].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Foscarnet; HIV; Huma | 1986 |
Lack of response to suramin in patients with AIDS and AIDS-related complex.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Complex; Clinical Trials as Topic; Drug Admi | 1987 |
12 other studies available for suramin and HIV
| Article | Year |
|---|---|
1984-Discovery of the First Anti-HIV Drug, Suramin.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Discovery; History, 20th Century; History, | 2021 |
Screening anti-HIV Chinese materia medica with HIV and equine infectious anemic virus reverse transcriptase.
Topics: Animals; Antiviral Agents; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; HIV; HIV Reverse Tra | 1994 |
Effect of polyanionic compounds on intracutaneous and intravaginal herpesvirus infection in mice: impact on the search for vaginal microbicides with anti-HIV activity.
Topics: Acrylic Resins; Animals; Antiviral Agents; Dextran Sulfate; Drug Evaluation, Preclinical; Female; He | 1995 |
Functional design of potential inhibitors of human immunodeficiency virus (HIV) binding to CD4+ target cells: a molecular model of gp120 predicts ligand binding.
Topics: Aurintricarboxylic Acid; Binding Sites; CD4 Antigens; Computer Simulation; Drug Design; HIV; HIV Env | 1996 |
Inhibition of gp120 binding to galactosyl ceramide and sulfatide by potential anti-HIV compounds.
Topics: Antiviral Agents; Drug Evaluation, Preclinical; Galactosylceramides; HIV; HIV Envelope Protein gp120 | 1992 |
Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. Differential activation and inhibition of protein kinase C isozymes.
Topics: Adenosine Triphosphate; Animals; Binding, Competitive; Brain; Calcium; Diglycerides; Enzyme Activati | 1990 |
Effect of retinoic acid on the replication of human immunodeficiency virus in HTLV-I-positive MT-4 cells.
Topics: Cell Line; Deltaretrovirus; HIV; Reverse Transcriptase Inhibitors; Suramin; Tretinoin; Viral Plaque | 1987 |
Persistence of human immunodeficiency virus antigenemia in patients with the acquired immunodeficiency syndrome treated with a reverse transcriptase inhibitor, suramin. Ten-patient case-control study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antigens, Viral; HIV; HIV Antigens; Humans; Lymphocytes; | 1988 |
Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells.
Topics: Antigens, Differentiation, T-Lymphocyte; Cell Line; Dextran Sulfate; Dextrans; Dideoxynucleosides; D | 1988 |
AIDS: the virus, antivirals and vaccines.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; Genes, Viral; HIV; Humans | 1987 |
In vitro suppression of HTLV-III/LAV infectivity by a combination of acyclovir and suramin.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Dose-Response Relationship, Drug; Drug Synergism; HIV | 1986 |
Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Complex; Drug Evaluation; Female; HIV; Human | 1987 |